Importantly, efficacy of MICAB1-PBD2G at low dose was observed in two-breast cancer PDXs, including HBCx-34 which is resistant to another ADC targeting trastuzumab emtansine (KADCYLA), targeting the HER2 tumor antigen38. This evidence concerns the gene ERBB2 and breast carcinoma.